CT-224

N/A

Report date: 2025/07/16 17:08:37

Base Information

Drug NameCT-224
Drug Alias NameCT224CT-224
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsCadherin-17 modulators
TargetsT cell surface glycoprotein CD3Cadherin-17
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai Cell Therapy Group Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Cell Therapy Group Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A